There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Medical Students
Residents and Fellows
Faculty Physicians
Allied Health Providers

NEEDS ASSESSMENT
We will review newly discovered disorders of the immune system and new treatment modalities for primary diseases of the immune system.

LEARNING OBJECTIVES:
At the end of this activity, participants will be able to:
1. Appreciate the mechanism of action of recombinant IL-18 binding protein
2. Understand the consequences of CD40L overexpression on lymphocytes
3. Review current and future therapies for chronic granulomatous disease

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Neil Romberg, MD: None
Pnina Weiss, MD, Grand Rounds Director: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.